Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TRU-015: Preliminary Phase IIb data

Preliminary data from double-blind Phase IIb trial in 276 RA patients showed that 1 of 4 TRU-015 doses (800 mg) met

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE